Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Jurkat cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Antibiotic (1) Apoptosis (8) Autophagy (2) Bacterial (1) Beclin1 (1) Casein Kinase (3) Caspase (1) CDK (2) CRAC Channel (1) Deubiquitinase (1) DGK (2) Drug Metabolite (1) Endogenous Metabolite (5) Ferroptosis (1) Free Fatty Acid Receptor (1) Fungal (1) HDAC (1) HIV (1) IFNAR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (3) Interleukin Related (2) Itk (3) JAK (2) MALT1 (1) MAP4K (6) MDM-2/p53 (2) Microtubule/Tubulin (1) Molecular Glues (2) mTOR (1) Necroptosis (1) NF-κB (1) NO Synthase (1) P-glycoprotein (1) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (1) PKC (1) Potassium Channel (1) PROTACs (4) RIP kinase (4) Src (1) STING (4) TNF Receptor (1) γ-secretase (1)
By Research Areas:	Cancer (44) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (15) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Adenosine Receptor (1)

Antibiotic (1)

Apoptosis (8)

Autophagy (2)

Bacterial (1)

Beclin1 (1)

Casein Kinase (3)

Caspase (1)

CDK (2)

CRAC Channel (1)

Deubiquitinase (1)

DGK (2)

Drug Metabolite (1)

Endogenous Metabolite (5)

Ferroptosis (1)

Free Fatty Acid Receptor (1)

Fungal (1)

HDAC (1)

HIV (1)

IFNAR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Integrin (3)

Interleukin Related (2)

Itk (3)

JAK (2)

MALT1 (1)

MAP4K (6)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Molecular Glues (2)

mTOR (1)

Necroptosis (1)

NF-κB (1)

NO Synthase (1)

P-glycoprotein (1)

PD-1/PD-L1 (2)

Phosphodiesterase (PDE) (1)

PKC (1)

Potassium Channel (1)

PROTACs (4)

RIP kinase (4)

Src (1)

STING (4)

TNF Receptor (1)

γ-secretase (1)

By Research Areas:

Cancer (44)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (15)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155396

PRO-HD1

PROTACs HDAC Cancer

PRO-HD1 is a PROTAC HDAC6 degrader. PRO-HD1 degrades HDAC6 in A549 cells, and inhibits proliferation of Jurkat cells (IC₅₀: 5.8 μM) .

PRO-HD1	PROTACs HDAC	Cancer
PRO-HD1 is a PROTAC HDAC6 degrader. PRO-HD1 degrades HDAC6 in A549 cells, and inhibits proliferation of Jurkat cells (IC₅₀: 5.8 μM) .

HY-149206

HPK1-IN-33	MAP4K	Cancer
HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a K_i value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC₅₀s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively .

HY-112335

Lck Inhibitor III	Src Interleukin Related	Cancer
Lck Inhibitor III (compound 12h) is a potent Lck inhibitor, with an IC₅₀ of 867 nM. Lck Inhibitor III inhibits IL-2 synthesis in Jurkat cells, with an IC₅₀ of 1.270 μM .

HY-P5870

KTX-Sp2	Potassium Channel	Inflammation/Immunology
KTX-Sp2 is a potassium channel toxin. KTX-Sp2 effectively blocks three types of exogenous voltage-gated potassium channels: Kv1.1, Kv1.2 and Kv1.3. Ktx-Sp2 inhibits endogenous Kv1.3 and suppresses Ca ²⁺ signaling in Jurkat T cells. Ktx-Sp2 inhibits IL-2 secretion from activated Jurkat T cells .

HY-153702

JAK-IN-27	JAK	Cancer
JAK-IN-27 (compound 1) is an orally active and potent JAKS family kinase inhibitor with IC₅₀s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. JAK-IN-27 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=23.7 nM) .

HY-P3083

N-Myristoyl-Lys-Arg-Thr-Leu-Arg	PKC	Inflammation/Immunology
N-Myristoyl-Lys-Arg-Thr-Leu-Arg is a protein kinase C (PKC) inhibitor with an IC₅₀ value of 75 μM. N-Myristoyl-Lys-Arg-Thr-Leu-Arg inhibits IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat .

HY-153701

JAK-IN-26	JAK	Cancer
JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=17.2 nM) .

HY-145322

TMX-4116	Casein Kinase Molecular Glues	Cancer
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC₅₀s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma .

HY-142648A

(R)-MLT-985	MALT1	Cancer
(R)-MLT-985 (compound 11) is a potent MALT1 protease inhibitor with an IC₅₀ of 3 nM. (R)-MLT-985 has an IC₅₀ of 20 nM for MALT1-dependent IL-2 production in Jurkat cells. (R)-MLT-985 suppresses growth and aberrant CARD11/BCL10/MALT1 complex signaling in ABC-DLBCL cells .

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma .

HY-110177

SP-100030	NF-κB	Inflammation/Immunology
SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC₅₀s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA) .

HY-19344

Lifitegrast 2 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344A

Lifitegrast sodium 2 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-109151

Milategrast E6007	Others	Inflammation/Immunology
Milategrast is useful as cell adhesion inhibitor or cell infiltration inhibitor. Milategrast in vitro inhibites the adhesion of Jurkat cells to human fibronectin with an IC₅₀ of ＜5 μM .

HY-115756

4-Maleimidosalicylic acid

Others Others

4-Maleimidosalicylic acid is a polar maleimide, and does not suppress IL-2 production in JURKAT T cells .
HY-N1726

cis-Burchellin

cis-Burchellin is a bioactive neolignan with anti-allergic activity. cis-Burchellin inhibits IL-2 production in Jurkat T-cells .

4-Maleimidosalicylic acid	Others	Others
4-Maleimidosalicylic acid is a polar maleimide, and does not suppress IL-2 production in JURKAT T cells .

cis-Burchellin
cis-Burchellin is a bioactive neolignan with anti-allergic activity. cis-Burchellin inhibits IL-2 production in Jurkat T-cells .

HY-156085

LP23	PD-1/PD-L1	Cancer
LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC₅₀: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) .

HY-126193

JS-K	NO Synthase Apoptosis	Cancer
JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH . JS-K inhibits proliferation, induces apoptosis, and disrupts the cell cycle of Jurkat T acute lymphoblastic leukemia cells .

HY-N7087

Tulipalin A α-Methylene butyrolactone	Drug Metabolite
Tulipalin A (α-Methylene butyrolactone) is a glycoside. Tulipalin A is a causative allergen that induces Allergic contact dermatitides . Tulipalin A (α-Methylene butyrolactone) at low dose affects the functionality of immune cells, such as Jurkat T cells .

HY-14622

Necrostatin 2 5 Publications Verification	RIP kinase	Cancer
Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

HY-N6681

15-Acetoxyscirpenol	Caspase Bacterial Apoptosis Antibiotic	Infection
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3 .

HY-15760

Necrostatin-1 Maximum Cited Publications 220 Publications Verification Nec-1	RIP kinase Autophagy Indoleamine 2,3-Dioxygenase (IDO) Ferroptosis	Cancer
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC₅₀ of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC₅₀=182 nM). Necrostatin-1 is also an IDO inhibitor .

HY-N0990

1,5,15-Trimethylmorindol
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .

HY-157838

HMC-B17	MAP4K	Cancer
HMC-B17 is a selective, orally bioavailable HPK1 inhibitor (IC₅₀ = 1.39 nM) that potentiates anti-PD-L1 efficacy. HMC-B17 potently enhances the IL-2 secretion in Jurkat cells (EC₅₀ = 11.56 nM). HMC-B17 can be used for the research of cancer .

HY-144672

A2A receptor antagonist 2	Adenosine Receptor	Inflammation/Immunology Cancer
A2A receptor antagonist 2 (Compound 57) is a potent, highly selective adenosine A_2A receptor (A_2AR) antagonist with an IC₅₀ of 8.3 nM .

HY-148847

HPK1-IN-32

MAP4K Cancer

HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases .

HPK1-IN-32	MAP4K	Cancer
HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases .

HY-149232

HPK1-IN-35	MAP4K	Cancer
HPK1-IN-35 is a potent and selective HPK1 inhibitor with an IC₅₀ value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion .

HY-123802

BIO7662

Integrin Cancer

BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

BIO7662	Integrin	Cancer
BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

HY-149917

ITK degrader 1	Itk	Cancer
ITK degrader 1 is a highly selective degrader of *interleukin-2-inducible T-cell* kinase (ITK; DC₅₀*=3.6 nM in vivo* in mice). ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC₅₀=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 also shows good plasma exposure levels .

HY-160214

Perforin-IN-2	Others	Inflammation/Immunology
Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC₅₀=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells .

HY-146671

ITK inhibitor 5

Itk Cancer

ITK inhibitor 5 (compound 27) is a potent and selective ITK inhibitor with IC₅₀s of 5.6, 25 nM for ITK, BTK, respectively .

ITK inhibitor 5	Itk	Cancer
ITK inhibitor 5 (compound 27) is a potent and selective ITK inhibitor with IC₅₀s of 5.6, 25 nM for ITK, BTK, respectively .

HY-151369

AV123	RIP kinase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC₅₀=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC₅₀=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases .

HY-110052

TBCA	Casein Kinase	Cancer
TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC₅₀ of 110 nM and a K_i of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .

HY-146389

Anticancer agent 50	MDM-2/p53 P-glycoprotein	Cancer
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma .

HY-N12487

TRRAP-IN-1

Others Cancer

TRRAP-IN-1 (compound 1) is a potent inhibitor of MYC:TRRAP interaction that plays an important role in anti-tumor research .

TRRAP-IN-1	Others	Cancer
TRRAP-IN-1 (compound 1) is a potent inhibitor of MYC:TRRAP interaction that plays an important role in anti-tumor research .

HY-N3119

Paeoniflorigenone	Apoptosis	Cancer
Paeoniflorigenone, isolated as an active ingredient from the root of moutan cortex, induces apoptosis selectively in the cancer cell lines and exhibits antiproliferative effect .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-12521

GSK-5498A 3 Publications Verification	CRAC Channel	Inflammation/Immunology
GSK-5498A is a selective CARC channel inhibitor (IC₅₀: 1 μM). GSK-5498A inhibits mediators release from mast cells and pro-inflammatory cytokines release from T cells. GSK-5498A can be used in the research of inflammatory disorders .

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-107780

Cyclic-di-GMP c-di-GMP; cyclic diguanylate; 5GP-5GP	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .

HY-107780A

Cyclic-di-GMP sodium c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .

HY-107780B

Cyclic-di-GMP diammonium 2 Publications Verification c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .

HY-110382

Cyclic-di-GMP disodium 2 Publications Verification c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

HY-148174

JNJ-3790339	DGK	Cancer
JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective diacylglycerol kinase (DGKα) inhibitor with an IC₅₀ of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation .

HY-N8287

Oxaline	Microtubule/Tubulin	Cancer
Oxaline is a fungal alkaloid that can be isolated from Penicillium oxalicum. Oxaline inhibits tubulin polymerization, resulting in cell cycle arrest at the M phase .

HY-14942A

Berubicin hydrochloride RTA 744; WP 744; WP 769 hydrochloride	Apoptosis	Cancer
Berubicin hydrochloride (RTA 744) is a Doxorubicin (HY-15142A) analogue. Berubicin hydrochloride triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. Berubicin hydrochloride has proapoptotic and anti-leukemia activities. Berubicin hydrochloride can be used for cancer research .

HY-143461

CK2 inhibitor 3	Casein Kinase	Cancer
CK2 inhibitor 3 is a potent CK2 inhibitor with IC₅₀ value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases .

HY-14174

MRK-560	γ-secretase	Neurological Disease Cancer
MRK-560 is an orally active, brain barrier-penetrating γ-Secretase inhibitor, can potently reduces Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 also decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) .

HY-151426

Anticancer agent 83	Apoptosis	Cancer
Anticancer agent 83 is a potent anticancer agent, inhibits LOX IMVI cells growth with a GI₅₀ value of 0.15 mM. Anticancer agent 83 reduces mitochondrial membrane potential and induces DNA damage to induces leukemia cells apoptosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7087

Tulipalin A α-Methylene butyrolactone	Liliaceae Ketones, Aldehydes, Acids Source classification Tulipa gesneriana L. Plants	Drug Metabolite
Tulipalin A (α-Methylene butyrolactone) is a glycoside. Tulipalin A is a causative allergen that induces Allergic contact dermatitides . Tulipalin A (α-Methylene butyrolactone) at low dose affects the functionality of immune cells, such as Jurkat T cells .

HY-N6681

15-Acetoxyscirpenol	Infection Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Disease Research Fields	Caspase Bacterial Apoptosis Antibiotic
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3 .

HY-N12487

TRRAP-IN-1	Structural Classification Natural Products Leguminosae Source classification Bituminaria morisiana (Pignatti & Metlesics) Greuter Plants	Others
TRRAP-IN-1 (compound 1) is a potent inhibitor of MYC:TRRAP interaction that plays an important role in anti-tumor research .